Cytokinetics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good. Awesome. Well, thanks everyone for joining another session here. Excited to be here with the Cytokinetics team of Isaac Ciechanover, CBO, Steve Heitner, CMO, Jeff Lotz, U.S. Sales and Ops VP, and Sung Lee, CFO. Lots to discuss, a lot going on in the HCM space, so maybe we can just get right into it, and it would be great to maybe just start with a brief overview of sort of the quarter and kind of some of your key takeaways now that we are kind of into the aficamten launch.
Sure. First of all, thanks so much for giving us the opportunity to come and speak. It was a great quarter, if you look at it from all metrics. Revenue was up 76% versus Q2, patient dispense greater than 2,800 versus 1,500.
CMI market, a year-over-year growth of 45%. On the regulatory side, we are now approved in five countries, five regions, and Europe is expanding. We have a number of upcoming important events with the sNDA of MAPLE-HCM next week. We have nHCM by the end of the year, the submission. Earlier in 2027, we will have in Europe. On the pipeline side, we released the data of ACACIA-HCM at ESC. We just have completed the main study treatment period for CAMELLIA-HCM in Japan.
All of this great movement forward, and it really puts us in a very strong position.
Yeah. No, totally. I think there's a pretty strong appreciation that the aficamten launch is going really well. I think one of the most interesting metrics is you're already nearing new-to-brand share sort of preference, or new start preference. I guess maybe what's really driving that, and what have you seen so far in sort of the launch in terms of the pushes and pulls here, and what's really having docs gravitate towards aficamten over CAMZYOS?
We're seeing, obviously, an expansion of prescribers and then increased productivity in each one of those trialists that start up.
The primary drivers are a differentiated clinical profile, which directly translates into a REMS that is, I guess, less burdensome on a comparative basis. All the things that you would expect to hear, rapidity with efficacy, flexible dosing and monitoring, shorter half-life on the safety side, no excursions in SEQUOIA-HCM.
which translates into a REMS where we just monitor safety at the current dose.
Yeah. It doesn't have some of the other complicated or burdensome measures that the competition has.
Yeah, makes sense. Are you seeing docs sort of take advantage of that flexibility as it relates to dosing, the monitoring echoes? Are they sort of Yeah fitting it into their workflow in an easier way?
Yeah. The titration and monitoring window, two to eight weeks, we see them using the full window.
There's some that are very aggressive, and it's usually patient-dependent, and they'll try to push the dose every two.
But I think on average right now, we're seeing people in that four to six weeks.
Some people just put it into the same workflow that they're accustomed to and monitor at week four, but we are seeing use of the full window.
Yeah. I think one of the other, especially as it relates to expanding the prescriber breadth of this class, is that you already have a meaningful number of prescribers in these low-volume or CMI-naive patients or prescribers. Maybe kind of just expand on that dynamic, how you see that evolving over time, and who are these docs? Are they people who wanted to use this class but just didn't want to use CAMZYOS, or is it just part of this broader momentum of the community getting more comfortable with these agents?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
